RE: Request for addition of Larotrectinib®(Vitrakvi) in the NCCN Clinical Practice Guidelines for Occult Primary™

On behalf of Bayer HealthCare Pharmaceuticals, I respectfully request the NCCN Panel to review the enclosed data (1-3) for potential tumor agnostic inclusion of Larotrectinib®(Vitrakvi) which was approved November 26, 2018. (4)

Specific Changes: We respectfully suggest the following for NCCN consideration:

- **OCC-1, Initial Evaluation:** Add “NTRK gene fusion testing”
- **MS-5, Molecular Profiling:** Add “NTRK testing should be conducted as part of broad molecular testing. Larotrectinib is recommended for tumors harboring an NTRK gene fusion.”
- **OCC-A, Potential Immunohistochemistry Markers for Unknown Cancer:** Add “TRK protein testing should be conducted as part of broad immunohistochemistry testing (a positive test should then be confirmed with NGS)”

**FDA Clearance:** (approval November 26, 2018) – FDA approved Larotrectinib (Vitrakvi®) for the treatment of adult and pediatric patients with solid tumors harboring a neurotropic receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, have metastatic disease or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments of that have progressed following treatment. (4)

Rationale: A total of 55 patients with TRK fusion-positive cancers were enrolled in one of three protocols (phase I adults, phase I/II adults and children and phase II study involving adolescents and adults). (1-5) These patients represented 17 unique TRK fusion-positive tumor types. TRK fusions were identified by next generation sequencing or fluorescence in situ hybridization. All testing was performed in Clinical Laboratory Improvement Amendments certified or equivalent independent laboratories.

**Overall evidence:**
- Of the 55 patients (primary analysis set) enrolled at primary data cutoff (July 17, 2017), the ORR was 75% according to independent review. At one year, 71% of the responses were ongoing and 55% of patients remained progression-free. (1, 2)
- In an update of an additional 54 evaluable patients (July 30, 2018), the ORR by investigator assessment was 81% (95 CI 69-91%; 17% CR, 65% PR). In these patients, with median follow-up of 7.4 months, 13 patients continue on study and await response assessment. (3)
Adverse events (AEs) were predominantly grade 1, with dizziness, increased AST/ALT, fatigue, nausea and constipation the most common AEs reported in ≥10% of patients. No AE of grade 3 or 4 related to larotrectinib occurred in more than 5% of patients. (1-4)

We appreciate your review and consideration of this recommendation.

Sincerely,

Joseph Germino, MD, PhD
Vice President
US Medical Affairs, Oncology
Bayer Healthcare Pharmaceuticals
100 Bayer Boulevard, P.O. Box 915
Whippany, N.J. 07981
(862) 404-5184

Reference List